Although our current study focuses primarily on lung adenocarcinoma (LUAD) and identifies PECAM1 as a potential prognostic biomarker, these findings collectively underscore the growing importance of subtype-specific biomarkers in NSCLC. This evidence concerns the gene PECAM1 and non-small cell lung carcinoma.